Legal status in the United States
Is Fragment 176-191 legal?
Read at FDA, DEA and WADAPublished by PepVault
Fragment 176-191 has no FDA-approved product, is not a federally controlled substance, and is banned in sport (WADA names it under S2.2.3), as of November 18, 2026.
Fragment 176-191 at a glance
| Check | Status, read Nov 18, 2026 |
|---|---|
| FDA approval | Not approved |
| Compounding | Not named on FDA’s lists |
| DEA schedule | Not controlled |
| Sport (WADA) | Banned, named (S2.2.3) |
FDA approval
Fragment 176-191 (hGH 176-191) has no FDA-approved product: Drugs@FDA lists no application for it.
- Drugs@FDA data (openFDA): applications listing “176-191” as an active ingredient, U.S. Food and Drug Administration. Read .

Compounding
FDA’s compounding lists don’t name it: not in any of the three 503A categories on FDA’s list updated May 14, 2026, not on FDA’s category 2 page, and not on the 503B bulks list.
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (updated May 14, 2026), U.S. Food and Drug Administration. Read .
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of April 22, 2026), U.S. Food and Drug Administration. Read .
- 503B Bulk Drug Substances List (content current as of May 16, 2024), U.S. Food and Drug Administration. Read .
DEA schedule
It is not a federally controlled substance: its name is not in the DEA’s schedules (21 CFR Part 1308) or on the DEA’s alphabetical list of controlled substances.
- 21 CFR Part 1308, Schedules of Controlled Substances (eCFR, up to date as of November 16, 2026), Electronic Code of Federal Regulations. Read .
- Controlled Substances, Alphabetical Order (dated November 17, 2026), Drug Enforcement Administration, Diversion Control Division. Read .
Sport (WADA)
WADA bans it at all times, in and out of competition: the 2026 list names “hGH 176-191” under S2.2.3, as a growth hormone fragment.
The source: “growth hormone fragments, e.g. AOD-9604 and hGH 176-191”
- World Anti-Doping Code International Standard, Prohibited List 2026 (in effect from January 1, 2026), World Anti-Doping Agency. Read .
How it is sold when it isn’t approved
FDA has warned companies that sold unapproved GLP-1 drugs labeled “for research purposes” or “not for human consumption” to consumers with dosing instructions, and calls that label false. FDA’s page names GLP-1 drugs; a research label is not an FDA approval of any kind.
The source: falsely labeled “for research purposes” or “not for human consumption.”
- FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (content current as of October 1, 2026), U.S. Food and Drug Administration. Read .
What this means and doesn’t
This page reports what the agencies’ own pages said about Fragment 176-191 in the United States when we read them on November 18, 2026. These are records of regulators, not study evidence; for what the research shows, see the compound page.
It is not legal advice, and it doesn’t cover state laws or other countries, whose rules differ. Agencies change their lists, so each fact carries its date and a link to the page it came from.
Questions
Is Fragment 176-191 FDA approved?
Fragment 176-191 (hGH 176-191) has no FDA-approved product: Drugs@FDA lists no application for it.
Is Fragment 176-191 a controlled substance?
It is not a federally controlled substance: its name is not in the DEA’s schedules (21 CFR Part 1308) or on the DEA’s alphabetical list of controlled substances.
Is Fragment 176-191 banned in sport?
WADA bans it at all times, in and out of competition: the 2026 list names “hGH 176-191” under S2.2.3, as a growth hormone fragment.
What does FDA say about compounding Fragment 176-191?
FDA’s compounding lists don’t name it: not in any of the three 503A categories on FDA’s list updated May 14, 2026, not on FDA’s category 2 page, and not on the 503B bulks list.
What does FDA say about the “research use only” label?
FDA has warned companies that sold unapproved GLP-1 drugs labeled “for research purposes” or “not for human consumption” to consumers with dosing instructions, and calls that label false. FDA’s page names GLP-1 drugs; a research label is not an FDA approval of any kind.